[Sugammadex, a revolutionary new drug to reverse neuromuscular block].
Alvarez Gómez
J A
JA
D000732:Androstanols / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D015394:Molecular Structure; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000097:blood; D000077123:Rocuronium; D055672:Static Electricity; D013329:Structure-Activity Relationship; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000732:Androstanols; D002800:Cholinesterase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D000077123:Rocuronium